6 hours ago
1
Anthem Biosciences IPO: The Bengaluru-based company, Anthem Biosciences, has secured Rs 1,016 crore from anchor investors ahead of its upcoming Initial Public Offering (IPO), which opens for public subscription on July 14.
According to the BSE website, the company has allotted 1.78 crore equity shares to 60 anchor investors at Rs 570 per share, which is the upper end of the IPO price band.
Anthem Biosciences anchor book list
The anchor book saw participation from several prominent global and domestic institutional investors. Here is the list:
- Abu Dhabi Investment Authority
- Government Pension Fund Global
- Eastspring Investments
- Amundi Funds
- PineBridge Global Funds
- Société Générale
- HDFC MF
- ICICI Prudential MF
- Axis MF
- UTI MF
- Quant MF
- Motilal Oswal MF
Anthem Biosciences IPO: Price band, lot size, key details
This issue is an offer for sale (OFS) by the company's promoters, investors and other personnel material. This means that the company will not get any benefit from this issue and it will be purely a variety of advice. However, information like lot size and price band has not been disclosed yet.
Price band, lot size
The company has fixed the price band between Rs 540 and Rs 570 per share. Investors can apply for 26 shares in a single lot and multiples lots.
Financial performance
The company reported revenue of Rs 1,844 crore in FY25, a 30 per cent year-on-year increase compared to Rs 1,419 crore in FY24. While its profit after tax (PAT) rose by 23 per cent to Rs 451 crore during the same period.
Listed competitors
The company has several listed industry peers, some of which are leaders in the sector, including Sai Life Sciences Limited, Syngene International, Suven Life Sciences and Divi's Laboratories.
BRLMs, registrar details
JM Financial, Citigroup Global Markets India, JP Morgan India, and Nomura Financial Advisory and Securities (India) are acting as the book-running lead managers for the IPO. The company has appointed Kfin Technologies Limited as registrar for the issues.
About Anthem Bioscience do?
Founded in 2006, Anthem Biosciences is a Contract Research, Development, and Manufacturing Organisation (CRDMO) focused on innovation and technology. The company operates across the entire pharmaceutical value chain, including drug discovery, development, and manufacturing. It also produces and markets complex fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
English (US) ·